Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics Inc (IOVA)
NASDAQ:IOVA
RESEARCH TOOLSreports
Holding IOVA?
Track your performance easily
IOVA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.70 - $18.33
Previous Close$7.46
Volume3.54M
Average Volume (3M)6.26M
Market Cap
$2.27B
Enterprise Value$1.96B
Total Cash (Recent Filing)$397.49M
Total Debt (Recent Filing)$78.94M
Price to Earnings (P/E)―
Beta2.50
Next Earnings
Feb 26, 2025EPS Estimate
-$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.50
Shares Outstanding304,780,790
10 Day Avg. Volume6,540,602
30 Day Avg. Volume6,258,477
Standard Deviation0.27
R-Squared0.01
Alpha0.00928
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)2.95
Price to Sales (P/S)25.02
Price to Cash Flow (P/CF)-9.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue21.52
Enterprise Value/Gross Profit-204.38
Enterprise Value/Ebitda-7.35
Forecast
1Y Price Target
$21.43Price Target Upside186.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Iovance Biotherapeutics News
PremiumCompany Announcements
Iovance Biotherapeutics Optimizes Headquarters for Cost Efficiency
PremiumCompany Announcements
Iovance Biotherapeutics’ Strong Q3 2024 Performance
Bulls Say, Bears Say
Bulls Say
Manufacturing CapabilitiesIovance fully controls their manufacturing capabilities and highlighted the uniqueness of owning their own TIL therapy-dedicated iCTC manufacturing facility.
Revenue GuidanceThe company remains confident in its revenue guidance and is well positioned in the early launch, despite the recent departure of its commercial head, and they see no impact from the Biosecures Act.
Sales GrowthIovance provided reassuring revenue guidance, supporting solid momentum in FY24 and FY25 for Amtagvi/Proleukin, with projected revenues above consensus.
Bears Say
Financial PerformanceA charge of $8.7M in cost of goods sold is related to scrap costs, indicating inefficiencies in manufacturing.
Operational ChallengesProlonged wait times for manufacturing slots are extending time to infusion and potentially limiting patient eligibility, impacting product uptake.
Product LaunchInitial metrics indicate a slow launch, with only about 10-15% of enrolled patients receiving the commercial product in the first quarter since approval.
---
Ownership Overview
9.63% Insiders
17.02% Mutual Funds
36.51% Other Institutional Investors
19.91% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IOVA FAQ
What was Iovance Biotherapeutics Inc’s price range in the past 12 months?
Iovance Biotherapeutics Inc lowest stock price was $6.70 and its highest was $18.33 in the past 12 months.
What is Iovance Biotherapeutics Inc’s market cap?
Currently, no data Available
When is Iovance Biotherapeutics Inc’s upcoming earnings report date?
Iovance Biotherapeutics Inc’s upcoming earnings report date is Feb 26, 2025 which is in 63 days.
How were Iovance Biotherapeutics Inc’s earnings last quarter?
Iovance Biotherapeutics Inc released its earnings results on Nov 07, 2024. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.299 by $0.019.
Is Iovance Biotherapeutics Inc overvalued?
According to Wall Street analysts Iovance Biotherapeutics Inc’s price is currently Undervalued.
Does Iovance Biotherapeutics Inc pay dividends?
Iovance Biotherapeutics Inc does not currently pay dividends.
What is Iovance Biotherapeutics Inc’s EPS estimate?
Iovance Biotherapeutics Inc’s EPS estimate is -$0.27.
How many shares outstanding does Iovance Biotherapeutics Inc have?
Iovance Biotherapeutics Inc has 304,780,800 shares outstanding.
What happened to Iovance Biotherapeutics Inc’s price movement after its last earnings report?
Iovance Biotherapeutics Inc reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.299. Following the earnings report the stock price went down -13.844%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics Inc?
Among the largest hedge funds holding Iovance Biotherapeutics Inc’s share is Perceptive Advisors LLC. It holds Iovance Biotherapeutics Inc’s shares valued at 250M.
---
Iovance Biotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.43 (186.11% Upside)
$21.43 (186.11% Upside)
Blogger Sentiment
Bullish
IOVA Sentiment 97%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $503.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.55%
12-Months-Change
Fundamentals
Return on Equity
-56.65%
Trailing 12-Months
Asset Growth
16.29%
Trailing 12-Months
Company Description
Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
---
IOVA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with significant revenue growth, successful commercial adoption of Amtagvi, and positive clinical trial results. Despite net losses and initial challenges in ATC performance, the overall sentiment is positive due to surpassing revenue expectations and a solid financial outlook.Read More>---
IOVA Stock 12 Month Forecast
Average Price Target
$21.43
▲(186.11% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Karyopharm Therapeutics
―
Arvinas Holding Company
―
Kura Oncology
―
Best Analysts Covering IOVA
1 Year
1 Year Success Rate
15/32 ratings generated profit
1 Year Average Return
+18.38%
reiterated a buy rating 10 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 46.88% of your transactions generating a profit, with an average return of +18.38% per trade.
---